Morgan Stanley Research: Experian to Log 7% Organic Revenue Growth in Fiscal Q1
Morgan Stanley Research expects Experian (EXPN.L) to log an organic rise in revenue when the data and technology company releases its fiscal first-quarter trading update on July 16. "We expect 1Q organic revenue growth of ~7%, within the FY27 guidance range (6-8%). This compares to ~9% printed for 4Q; while organic growth accelerated in 4Q, management noted higher rate expectations and some caution in parts of the market, though they expect broadly stable conditions in FY27, with the US and UK consumer remaining particularly resilient," the research firm said in a July 10 European earnings preview report. Looking ahead, Morgan Stanley expects the company's revenue to grow 7.6% and 8.7% organically for fiscal years 2027 and 2028, against the company-compiled consensus estimate of 7.2% and the Visible Alpha consensus of 7.5%, respectively. "Experian remains among the highest-quality names across our coverage, with long-term potential for sustained high-single-digit, defensive organic growth with margin expansion, driven by its ability to monetise proprietary data across an ever-expanding addressable market," Morgan Stanley noted, with the stock's rating remaining at.
Morgan Stanley Research expects Experian (EXPN.L) to log an organic rise in revenue when the data and technology company releases its fiscal first-quarter trading update on July 16. "We expect 1Q organic revenue growth of ~7%, within the FY27 guidance range (6-8%).
This compares to ~9% printed for 4Q; while organic growth accelerated in 4Q, management noted higher rate expectations and some caution in parts of the market, though they expect broadly stable conditions in FY27, with the US and UK consumer remaining particularly resilient," the research firm said in a July 10 European earnings preview report.
Looking ahead, Morgan Stanley expects the company's revenue to grow 7.6% and 8.7% organically for fiscal years 2027 and 2028, against the company-compiled consensus estimate of 7.2% and the Visible Alpha consensus of 7.5%, respectively. "Experian remains among the highest-quality names across our coverage, with long-term potential for sustained high-single-digit, defensive organic growth with margin expansion, driven by its ability to monetise proprietary data across an ever-expanding addressable market," Morgan Stanley noted, with the stock's rating remaining at.